These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 8718512)

  • 21. Diet, genetic polymorphisms, detoxification, and health risks.
    Lampe JW
    Altern Ther Health Med; 2007; 13(2):S108-11. PubMed ID: 17405687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity.
    Wormhoudt LW; Commandeur JN; Vermeulen NP
    Crit Rev Toxicol; 1999 Jan; 29(1):59-124. PubMed ID: 10066160
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Xenobiotic gene polymorphisms and susceptibility to multiple myeloma.
    Lincz LF; Kerridge I; Scorgie FE; Bailey M; Enno A; Spencer A
    Haematologica; 2004 May; 89(5):628-9. PubMed ID: 15136237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The glutathione S-transferases: influence of polymorphism on cancer susceptibility.
    Strange RC; Fryer AA
    IARC Sci Publ; 1999; (148):231-49. PubMed ID: 10493261
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility--a review.
    Raunio H; Husgafvel-Pursiainen K; Anttila S; Hietanen E; Hirvonen A; Pelkonen O
    Gene; 1995 Jun; 159(1):113-21. PubMed ID: 7607565
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility.
    Daly AK; Cholerton S; Armstrong M; Idle JR
    Environ Health Perspect; 1994 Nov; 102 Suppl 9(Suppl 9):55-61. PubMed ID: 7698086
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic polymorphisms in human drug-metabolizing enzymes: potential uses of reverse genetics to identify genes of toxicological relevance.
    Puga A; Nebert DW; McKinnon RA; Menon AG
    Crit Rev Toxicol; 1997 Mar; 27(2):199-222. PubMed ID: 9099519
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
    Zhou SF; Liu JP; Chowbay B
    Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Genetic polymorphisms in xenobiotic metabolizing enzymes as a determinant of susceptibility to environmental mutagens and carcinogens in humans].
    Ozawa S
    Yakugaku Zasshi; 1997 Nov; 117(10-11):895-909. PubMed ID: 9414599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polymorphism of drug-metabolizing enzymes in relation to individual susceptibility to industrial chemicals.
    Nakajima T; Aoyama T
    Ind Health; 2000 Apr; 38(2):143-52. PubMed ID: 10812837
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polymorphisms of xenobiotic-metabolizing enzymes and susceptibility to cancer.
    Hirvonen A
    Environ Health Perspect; 1999 Feb; 107 Suppl 1(Suppl 1):37-47. PubMed ID: 10229705
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic polymorphisms in human xenobiotica metabolizing enzymes as susceptibility factors in toxic response.
    Autrup H
    Mutat Res; 2000 Jan; 464(1):65-76. PubMed ID: 10633178
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic factors in individual responses to environmental exposures.
    Hirvonen A
    J Occup Environ Med; 1995 Jan; 37(1):37-43. PubMed ID: 7620941
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of human cytochrome P-450s in risk assessment and susceptibility to environmentally based disease.
    Gonzalez FJ; Gelboin HV
    J Toxicol Environ Health; 1993; 40(2-3):289-308. PubMed ID: 8230303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic factors in cancer susceptibility.
    Wolf CR
    Cancer Surv; 1990; 9(3):437-74. PubMed ID: 2101721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic genetic polymorphisms and susceptibility to lung cancer.
    Bouchardy C; Benhamou S; Jourenkova N; Dayer P; Hirvonen A
    Lung Cancer; 2001 May; 32(2):109-12. PubMed ID: 11325480
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Polymorphism of enzymes involved in drug metabolism: gene structure and enzymatic activity].
    Krynetskiĭ EI
    Mol Biol (Mosk); 1996; 30(1):33-42. PubMed ID: 8714120
    [No Abstract]   [Full Text] [Related]  

  • 38. Genetic polymorphisms and oral cancer.
    Taniyama Y; Takeuchi S; Kuroda Y
    J UOEH; 2010 Sep; 32(3):221-36. PubMed ID: 20857816
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I and Phase II enzyme polymorphisms and childhood cancer.
    Swinney R; Hsu S; Tomlinson G
    J Investig Med; 2006 Sep; 54(6):303-20. PubMed ID: 17134614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical significance of pharmacogenetics in dermatological diseases].
    Rychlik-Sych M; Barańska M; Skritkowicz J
    Przegl Lek; 2012; 69(3):120-4. PubMed ID: 22764654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.